This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Read More

Tardive Dyskinesia (TD) Treatment Market

Tardive Dyskinesia (TD) Treatment Market

Tardive Dyskinesia (TD) Treatment Market

Tardive Dyskinesia (TD) Treatment Market: Global Industry Analysis 2012 – 2016 and Opportunity Assessment; 2017 – 2027

Tardive Dyskinesia (TD) Treatment Market Overview

Tardive dyskinesia is a type of neurological disorder, which characterized the blink your eyes fast, chew, smack or pucker of lips, puff out your cheeks, tongue and others.  The patients treating with neuroleptic drugs or anti-psychotic medications can also be the cause of tardive dyskinesia.  Tardive dyskinesia is difficult to treat as treatment process is also not confirmed and the drug is also not approved in various conditions. The treatment of tardive dyskinesia is directly affect the neurological system of the respective patients. This disorder may commonly occurs in smoker than non-smoker, and also in the patient of depression, anxiety disorder and others.

Tardive Dyskinesia (TD) Treatment Market: Drivers and Restraints

Tardive Dyskinesia (TD) Treatment is a growing market over the forecast period, as the population suffering from the neurological disorder, for instance, a report published by Neurocrine Biosciences in April 2017, around 500,000 American population is suffering from tardive dyskinesia, this can drive the market looking forward for the treatment. The approval process from the respective association is the hindrance for this market.  

Tardive Dyskinesia (TD) Treatment Market: Overview

The market of the tardive dyskinesia treatment is the growing as the approval for the drug are coming, for instance, in April 2017, FDA has approve valbenazine for the treatment of tardive dyskinesia. Many research are also going on the drug combination and also on the side effect of this drug, so that the players can come with various drug combinations in the market.

Tardive Dyskinesia (TD) Treatment Market: Region-wise Outlook

Geographically, Tardive Dyskinesia (TD) Treatment Market is segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, Japan, Middle East and Africa. North America have the highest demand in the neurological drug, the players of North America are actively participating in the research to come up with advance drug to the treatment. Europe and Asia Pacific are also participating in the research and creating awareness about the treatment of tardive dyskinesia.   

Tardive Dyskinesia (TD) Treatment Market: Key Players

Some players in Tardive Dyskinesia (TD) Treatment Market include Neurocrine Biosciences, Inc., Teva Pharmaceutical Industries Ltd's, Pfizer Inc., Biogen, Novartis AG, Johnson & Johnson Services, Inc., AstraZeneca, GlaxoSmithKline plc., Bayer AG , and Sanofi.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil and Rest of Latin America)
  • Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg and Rest of Western Europe)
  • Eastern Europe (Poland, Russia and Rest of Eastern Europe)
  • Asia Pacific (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC, S. Africa, and Rest of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Tardive Dyskinesia (TD) Treatment Market: Segmentation

By Drug

  • Valbenazine
  • Others
  • Tetrabenazine
  • Amantadine
  • Clonazepam

By End User

  • Hospitals
  • Pharmacies
  • Drug stores

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint

Need specific information?

Our Clients


View All Reports from Healthcare

View Reports



Loop Mediated Isothermal Amplification Market

Published : 2019-03-15


Bioimpedance Device Market

Published : 2019-01-08


Anti Microbial Anti Fungal Tests Market

Published : 2017-11-09


Liquid Biopsy Market 112017

Published : 2017-11-13